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Table. Outcome of carotid endarterectomy vs stenting
Stroke or death
Stroke, death, or
myocardial infarction
Asymptomatic Symptomatic Asymptomatic Symptomatic
Normal
risk
High
risk
Normal
risk
High
risk
Normal
risk
High
risk
Normal
risk
High
risk
CAS 0.0% 0.0% 4.7% 7.9% 0.0% 0.0% 6.3% 7.9%
CEA 0.6% 1.3% 1.0% 1.9% 1.4% 2.6% 1.8% 2.9%
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Mortality in Patients Undergoing Aortic Reconstruction
Virendra I. Patel,1 Robert T. Lancaster,1 Emel Ergul,1 Mark F. Conrad,1
Daniel Bertges,2 Marc Schermerhorn,3 Phillip Goodney,4 Richard P.
Cambria1. 1Massachusetts General Hospital, Boston, Mass; 2Flether Allan
Medical Center, Burlington, Vt; 3Beth Israel Deaconess Medical Center,
Boston, Mass; 4Dartmouth-Hitchcock Medical Center, Lebanon, NH
Objectives: Preoperative chronic kidney disease (CKD) has been
shown to predict postoperative renal complications and late survival
following aortic surgery, whereas the impact of postoperative renal compli-
cations less severe than permanent dialysis are unknown. We evaluated the
effect of increasingly severe postoperative renal dysfunction on survival using
a regional quality improvement registry.
Methods: Patients undergoing intact open aortic reconstruction in
the Vascular Study Group of New England registry (2003-2012) were strat-
iﬁed by severity of postoperative renal complications; none, creatinine
increase >0.5 mg/dL (IncCr), or any dialysis (HD). Predictors of renal
dysfunction and impact of renal complications on survival were analyzed
using multivariable methods.
Results: A total of 2095 patients were included, of which 72% had
open abdominal aortic aneurysm repair, and 28% open aortoiliac reconstruc-
tion. Of these, 15% of patients had moderate CKD, and 1.2% had severe
CKD at baseline. Postoperatuve renal complications were none in 90%,
IncCr in 8.6%, and HD in 1.6%. Multivariable cumlogit regression identiﬁed
moderate CKD (odds ratio [OR], 2.7; 95% conﬁdence interval [CI], 1.8-3.9;
P< .01), severe CKD (OR, 17; 95% CI, 7-41; P< .01), operating room time
(OR, 1.004 minutes; 95% CI, 1.003-1.006; P < .01), and supra-renal clamp
use (OR, 2.1; 95% CI, 1.4-2.9; P < .01) as independent predictors of wors-
ening strata of postoperative renal dysfunction. Risk-adjusted multivariable
Cox regression showed that IncCr (hazard ratio, 1.6; 95% CI, 1.1-2.3;
P ¼ .01) and HD (hazard ratio, 3.2; 95% CI, 1.8-5.7; P < .01) increased
risk of late death independent of age, gender, baseline moderate or severe
CKD, congestive heart failure, chronic obstructive pulmonary disease, and
postoperative myocardial infarction or death. Five-year survival was lower
(log rank P < .01) in patients with IncCr (71% 6 4%), and HD (29% 6
10%) compared with those with none (79% 6 1%; Fig).
Conclusions: Increasing severity of postoperative renal dysfunction
independently predicts increased risk of late mortality after open aortic
surgery. Perioperative measures to reduce renal complications may poten-
tially prolong the survival of patients following open aortic surgery.P value .36 .33 <.01 <.01 .15 .17 <.01 .02
CAS, Carotid artery stenting; CEA, carotid endarterectomy.
Fig.Outcome of Carotid Endarterectomy Versus Stenting in Comparable
Medical Risk Patients
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Objectives: In medically high-risk patients, the choice between
carotid artery stenting (CAS) and carotid endarterectomy (CEA) can be
difﬁcult. The purpose of this study was to compare risk-stratiﬁed outcomes
of CAS and CEA.Methods: Patients undergoing primary CEA (n ¼ 10,541) or primary
CAS (n ¼ 424) at 26 centers in the Vascular Study Group of New England
were analyzed (2003-2012); patients with prior ipsilateral CEA or CAS
were excluded. A medical risk score based on the risk of death within 5 years
was developed for each patient using a Cox proportional hazards model.
Patients in the highest risk quartile were termed high-risk (vs normal risk
for the other three quartiles). Risk-stratiﬁed outcomes were compared
between neurologically symptomatic and asymptomatic patients.
Results: Patients undergoing CAS had a higher prevalence of coro-
nary artery disease, congestive heart failure, diabetes, chronic obstructive
pulmonary disease, and contralateral internal carotid artery occlusion.
Neurologic symptom status was not different (CAS, 43% vs CEA, 40%
symptomatic). Overall 5-year survival was 80%. Medically high-risk patients
had a 5-year survival of 60% and comprised 25% of CEA and 35% of CAS.
Among asymptomatic patients rates of in-hospital stroke/death, and
stroke/death/myocardial infarction were not different between CAS and
CEA in both normal- and high-risk cohorts. Among symptomatic patients,
CAS had signiﬁcantly higher event rates for both normal- and high-risk
cohorts (Table). CAS outcomes did not correlate with operator annual-
ized stent volume.
Conclusions: In the Vascular Study Group of New England, asymp-
tomatic normal- and high-risk patients do equally well after CEA or CAS.
However, both normal- and high-risk symptomatic patients have substan-
tially worse outcomes with CAS as compared with CEA. Symptom status
is more important than medical risk when recommending CAS.Racial Disparity in Hemodialysis Access Types in Patients with End-
Stage Renal Disease: An Analysis of the United States Renal Database
System
Devin S. Zarkowsky, Joseph Canner, Eric Schneider, Umair Qazi,
Christopher J. Abularrage, Thomas Reifsnyder, Bruce A. Perler, Julie A.
Freischlag, Mahmoud Malas. The Johns Hopkins Hospital, Baltimore, Md
Objectives: To examine racial and ethnic inﬂuences on hemodialysis
initiation modes with arteriovenous ﬁstula (AVF), arteriovenous graft
(AVG), and intravenous hemodialysis (HD) catheter (IHC) in patients
with end-stage renal disease (ESRD).
Methods: A retrospective analysis of a prospectively collected data-
base comprising all ESRD patients receiving renal replacement therapy
maintained by the United States Renal Database System between 2006
and 2010 was performed with institutional review board approval. c2 tests
and analysis of variance provided descriptive statistics.
Results: Examined were 2,377,166 ESRD patients. We excluded all
patients with IHC, AVF, or AVG prior to 2006, those not classiﬁed as white,
black, orHispanic, and patients with prior kidney transplants. Patients totaling
482,988 were included, of whom 82.7% initiated HD via IHC versus 13.9%
via AVF and 3.4% via AVG.White patients were older (65.9 years) at initiation
than black (58.4 years) and Hispanic (58.0 years) patients (P < .001). Black
patients were more likely to be female (48.1%) than white (41.2%) and
Hispanic (42.9%) patients (P < .001). HD initiation with AVF was more
common among white patients (15.2%) than black (12.5%) or Hispanic
(11.8%) patients, whereas AVG was more common among black patients
(4.9%) than white (2.9%) or Hispanic (2.6%) patients (P < .001; Table).
Conclusions: White ESRD patients initiate HD with AVF more
frequently than black or Hispanic patients. This disparity between white
and black patients derives not from procedure rate, but rather from conduit
selection. Black patients receive AVG two-thirds more frequently, while
undergoing surgery at clinically similar rates. Hispanic patients receive fewer
ﬁstulas and grafts, as well as more catheters, in comparison to the other
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tive targets 50% hemodialysis initiation with ﬁstulas, a benchmark beckoning
improvement in current ESRD care.Table. Hemodialysis initiation characteristics for ESRD patients in the
United States
White
(n ¼ 264,350)
Black
(n ¼ 148,808)
Hispanic
(n ¼ 69,830) P value
Mean age (SD) 65.9 (15.3) 58.4 (15.4) 58.0 (16.6) <.001
Female (%) 122,066 (41.2) 76,286 (48.1) 32,588 (42.9) <.001
AVF (%) 40,206 (15.2) 18,663 (12.5) 8,221 (11.8) <.001
AVG (%) 7,578 (2.9) 7,271 (4.9) 1,785 (2.6) <.001
IHC (%) 216,566 (81.9) 122,874 (82.6) 59,824 (85.7) <.001
AVF, Arteriovenous ﬁstula; AVG, arteriovenous graft; ESRD, end-stage
renal disease; IHC, intravenous hemodialysis.Thioglitazones Improve SFA Stenting Primary Patency Rates in
Diabetics
Karen L. Walker,1 Kathleen A. Martin,2 Julia D. Glaser,1 Philip P.
Goodney,1 Daniel B. Walsh,1 David H. Stone,1 Richard J. Powell,1 Eva
M. Rzucidlo1. 1Dartmouth Hitchcock Medical Center, Lebanon, NH;
2Yale School of Medicine, New Haven, Conn
Objectives: Low adiponectin levels are predictive of in-stent resteno-
sis for bare-metal coronary stents. Thioglitazone (TZD) treatment increases
adiponectin levels and decreases in-stent restenosis in coronary stents. Adi-
ponectin is secreted by vascular smooth muscle cells (VSMCs) and adipo-
cytes. Adiponectin promotes the quiescent phenotype of VSMCs leading
to less intimal hyperplasia. We hypothesize that diabetic patients on TZDs
have better superﬁcial femoral artery (SFA) stent primary patency rates
than diabetics not on TZDs.
Methods: Our institution maintains a database for SFA interventions.
Patients who underwent primary SFA stenting were identiﬁed. We excluded
patients undergoing concomitant tibial stenting. Student t-test, c2, and log
rank were used for the statistical analysis.
Results: We identiﬁed 108 diabetic patients who had a total of 118
limbs stented between January 2000 and December 2010. Twenty patients
were taking a TZD at the time of their SFA stent. Sixty-ﬁve percent of
TZD patients were treated for claudication vs 42% of patients not taking
TZDs (P ¼ .06). Patients taking TZDs were older (mean age, 69.1 vs 63;
P ¼ .03). No statistically signiﬁcant differences were identiﬁed for hyperten-
sion, hyperlipidemia, coronary artery disease, renal insufﬁciency, history of
smoking, and statin use. Survival analysis showed signiﬁcantly improved
primary patency for patients on TZDs (Fig; P ¼ .04). At 3 years, TZD
primary patencywas higher at 86% comparedwith 55% for diabetic patients not
on TZDs.
Conclusions: This translational research study demonstrates the novel
ﬁnding that diabetic patients on TZDs have better SFA stenting primaryFig.patency than diabetics not on TZDs. Improved primary patency leads to
less reinterventions and medical cost. Future work will evaluate the useful-
ness of adiponectin as a biomarker and therapeutic target.ACE Inhibitors Improve Outcomes in Percutaneous Infrainguinal
Interventions
James W. Cornwall, Riju Banerjee, Daniel Han, David L. Ku, Robert
Lookstein, Victoria J. Teodorescu, Michael L. Marin, Peter L. Faries, Ageliki
G. Vouyouka. Icahn School of Medicine at Mount Sinai, New York, NY
Objectives: The favorable effects of angiotensin-converting-enzyme
(ACE) inhibitors on different aspects of cardiovascular disease and manage-
ment are not well understood. We evaluated the impact of ACE inhibitors
on postoperative outcomes in interventions for peripheral arterial disease
(PAD) by analyzing infrainguinal endovascular procedures from December
2004 to June 2012 in patients taking ACE inhibitors (AI) and not taking
ACE inhibitors (NAI).
Methods: Comparisons between AI and NAI were made using c2
tests and Kaplan-Meier survival curves. Multivariate regression analysis
was performed using the Cox proportional hazard model.
Results: A total of 149 patients (38.3% AI, 61.7% NAI) had 316 index
lesions (35.1% AI, 64.9% NAI). NAI were more likely to be female (66.7% vs
33.3%; P ¼ .001) and older at time of surgery (69.6 6 11.5 vs 74.0 6 12.4
years old; P¼ .002). NAI were more likely to have tissue loss than AI (84.6%
vs 72.3%; P ¼ .016). The mean follow-up time was 25.07 months. Primary
(at 18 months, 53.5% vs 47.7%; P ¼ .6) and secondary patency (at 18
months, 87.3% vs 81.7%; P ¼ .235) were equivocal in AI and NAI groups.
There was a strong trend favoring primary assisted patency in AI (at 18
months, 84.3% vs 70.7% in NAI; P ¼ .053) that did not reach statistical
signiﬁcance. Limb salvage was superior in AI (at 18 months, 97.8% vs
85.0% in NAI; P value ¼ .025). After controlling for diabetes, hypertension,
end-stage renal disease, hypercholesterolemia, coronary artery disease, TASC
score, smoking status, age, and tissue loss, AI usage was an independent posi-
tive predictor of limb salvage (P ¼ .007; relative risk, 0.082).
Conclusions: This data suggests that AI therapy is associated with
a beneﬁcial effect on the outcomes of percutaneous infrainquinal interven-
tions for PAD. Further understanding of the relationship between AIs
and limb salvage may help us improve the management of PAD.Why Wait? Concurrent Venogram During First Rib Resection for
Venous Thoracic Outlet Syndrome Is Safe and Efﬁcient
Alexander T. Hawkins, Maria J. Schaumeier, Ann D. Smith, Marit S.
DeVos, Karen J. Ho, Marcus E. Semel, Louis L. Nguyen. Brigham and
Women’s Hospital, Boston, Mass
Objectives: Surgical treatment of venous thoracic outlet syndrome
(VTOS) traditionally involves ﬁrst rib resection (FRR) followed by interval
venogram and balloon angioplasty. This approach can lead to an extended
need for anticoagulation and a separate anesthesia session. We present
outcomes for FRR with concurrent venogram.
Methods: Retrospective chart review was performed for consecutive
patients undergoing FRR with concurrent venogram for idiopathic VTOS
from 2/2007 to 2/2013. Venograms were performed immediately after
FRR with the arm in neutral and provocative positions. The primary
outcome was modiﬁcation of procedure following venogram. Secondary
outcomes were subclavian vein (SCV) patency, duration of anticoagulation,
and symptom relief.
Results: Twenty-four patients underwent FRR with venogram with
a mean follow-up time of 32.4 months. The mean age was 28.5 years (range,
17-52 years), and 14 (58.3%) were female. All were maintained on anticoagu-
lation prior to the procedure. Concurrent venogram resulted in modiﬁcation
of the procedure in 22 patients (91.7%). Of these, 21 patients (95.4%) under-
went balloon angioplasty, and one patient (4.5%) underwent further rib resec-
tion. Fifteen patients (62.5%) were discharged after the procedure with no
anticoagulation. For those receiving postoperative anticoagulation for persis-
tent minor thrombus, median time for anticoagulation duration was 5.6
months (range, 0.8-28.7 months). Two patients (8.3%) had postoperative
bleeding requiring thoracentesis or video-assisted thorascopic evaculation of
hemothorax. One patient (4.2%) suffered rethrombosis and was successfully
lysed open, resulting in a 2-year SCV primary patency of 95.8% and primary-
assisted patency of 100%. No patients required reoperation for VTOS and all
reported improvements in symptoms. Two patients (8.3%) underwent
prophylactic FRR on contralateral side for symptoms and SCV stenosis.
Conclusion: FRR with concurrent venogram is a safe procedure for
VTOS that allows for effective intraoperative modiﬁcation of the surgical
plan, resulting in excellent SCV patency, early cessation of anticoagulation,
and durable symptom relief.
